Alteration of N‐glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma. Issue 9 (13th January 2015)

• Record Type: Journal Article
• Authors: Miyahara, Koji; Nouso, Kazuhiro; Dohi, Chihiro; Morimoto, Yuki; Kinugasa, Hideaki; Wada, Nozomu; Takeuchi, Yasuto; Kuwaki, Kenji; Onishi, Hideki; Ikeda, Fusao; Miyake, Yasuhiro; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Amano, Maho; Nishimura, Shin‐Ichiro; Yamamoto, Kazuhide
• Is Part Of: Hepatology research. Volume 45:Issue 9(2015:Sep.)
• Page Start: 986
• Page End: 993
• Publication Date: 2015-01-13
• Subjects: Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12441
• Languages: English
• ISSNs: 1386-6346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hepr12441-sec-0001" sec-type="section"> <title>Aim</title> <p>Most of the modification of <italic>N</italic>‐glycosylation reported in cancers including hepatocellular carcinoma (HCC) were based on the examinations of a small number of patients or particular proteins. The aim of this study is to reveal changes in whole serum <italic>N</italic>‐glycan profiles systematically during the process of hepatocarcinogenesis and to elucidate their clinical application.</p> </sec> <sec id="hepr12441-sec-0002" sec-type="section"> <title>Methods</title> <p>We analyzed sera from 105 patients with chronic hepatitis/liver cirrhosis (CH/LC) and age‐/sex‐matched healthy volunteers (HLT), as well as from 114 patients with HCC. Serum <italic>N</italic>‐glycan profiles were measured comprehensively by a new, quantitative, high‐throughput method and compared with clinical parameters.</p> </sec> <sec id="hepr12441-sec-0003" sec-type="section"> <title>Results</title> <p>The total amount of <italic>N</italic>‐glycan expression was significantly higher in patients with CH/LC than in HLT; however, no differences were observed between CH/LC and HCC patients. In HCC patients, multi‐antennary glycans with fucose residues, particularly <italic>m/z</italic> 3195, were increased compared with CH/LC patients. The expression of <italic>m/z</italic> 3195 was high, especially in patients with a high number of intrahepatic lesions (>3), large tumor size (>3 cm), macroscopic vascular invasion or metastasis. The ratio of pairs of glycans on the same path of the biosynthesis pathway (<italic>m/z</italic> 3195/1914) showed a higher area under the receiver–operator curve of 0.810 than any other single glycan to distinguish HCC from CH/LC.</p> </sec> <sec id="hepr12441-sec-0004" sec-type="section"> <title>Conclusion</title> <p>We demonstrate the full spectrum of the alterations of serum <italic>N</italic>‐glycans comprehensively in patients with liver disease, and elucidate the possible use of glycans as novel biomarkers of liver disease progression.</p> </sec> </abstract>